PGL prospa group limited.

pillman predicts - bioshares article on pgl, pglaf

  1. 2,076 Posts.

    PROGEN - PGL

    http://www.progen.com.au/investorinformation/index.cfm

    Progen is a veteran Biotech getting EXCELLENT coverage in this week's bioshares www.bioshares.com.au (no, i cant post it - i paid for the info and it's copyright, but i encourage you to pay the $220 for one year subscription). Progen went from $1.00 a share to $100 a share in 1990ish, however has been in decline ever since and is now on the bounce .

    They have a HEAP of patents and trials in phases 1-3, and various things in development.

    On the back of this weeks Bioshares article I expect a lot of interest in this, but that in itself isnt enough

    PGLAF is the nasdaq ticker symbol, PGL is the ASX symbol. PGLAF jumped 14% overnight on some strong numbers coming back from various opps.

    WHY DO I LIKE THEM

    They have existing contracts in place and are already cash positive

    They have come out of a slump that has made them undervalued

    The things they are testing relate to cancer related treatments and are experiencing high success rates

    They have a HEAP of patents. . . i mean HEAPS

    They are capitolised at 53m, and have 12m in cash, that hasnt just come from writing more shares like MUL

    WHAT DO I PREDICT

    A jump this week on the back of the good article, followed by a small increase over the coming weeks. There is significant upside in this company that hasnt been seen yet in the market.,

    Given the solid pipeline of developments, successes and the R+D portfolio (as well as the fact they make money already) this is an excellent stock

    I am holding PGL
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.